| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Palbociclib |
| Brand | Ibrance® |
| Indication | For the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer. |
| Assessment Process | |
| Rapid review commissioned | 20/09/2016 |
| Rapid review completed | 28/09/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 10/10/2016 |
| Pre-submission consultation with Applicant | 11/11/2016 |
| Full submission received from Applicant | 20/12/2016 |
| Preliminary review sent to Applicant | 24/05/2017 |
| NCPE assessment re-commenced | 30/05/2017 |
| Follow-up to preliminary review sent to Applicant | 13/06/2017 |
| NCPE assessment re-commenced | 15/06/2017 |
| Additional follow-up to Preliminary Review sent to Applicant | 16/06/2017 |
| NCPE assessment re-commenced | 21/06/2017 |
| Factual accuracy sent to Applicant | 04/07/2017 |
| NCPE assessment completed | 28/07/2017 |
| NCPE assessment outcome | Reimbursement not recommended. |
The HSE has approved reimbursement following confidential price negotiations; June 2018.
